Share This Article:

The Effect of a Psycho-Educational Program on Psychiatric Symptoms, Drug Attitude and Treatment Satisfaction of Patients with Schizophrenia

Full-Text HTML XML Download Download as PDF (Size:301KB) PP. 229-237
DOI: 10.4236/ojpsych.2015.53027    2,705 Downloads   3,140 Views  

ABSTRACT

The purpose of this study was to determine the effect of a Comprehensive Psycho-Educational Approach and Scheme Set (COMPASS) for patients with schizophrenia who were treated with risperidone long-acting injectable (RLAI), on their psychiatric symptoms, drug attitudes, and treatment satisfaction levels. Participants were sixty-five patients at thirteen hospitals in Japan who met ICD-10 F2 criteria for schizophrenia or schizo-affective disorder and were treated with RLAI. A correlational study design was used to measure the effect of the COMPASS on the psychiatric symptoms, drug attitudes, and treatment satisfaction levels of patients treated with RLAI. Using the following evaluation indicators: The Subjective Satisfaction to Treatment Scale (SSTS), Brief Psychiatric Rating Scale (BPRS), Global Assessment of Functioning (GAF), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), and Drug Attitude Inventory-10 (DAI-10), measurements were taken at the beginning of the program (baseline), at the end of the program, and six months after (endpoint). Data analysis included descriptive statistics, Mann-Whitney U test or Wilcoxon signed-rank test, and Spearman’s rank correlation coefficient. Significant differences were observed in BPRS total (p < 0.001), sub-scales of BPRS positive (p < 0.001), BPRS negative (p < 0.01), BPRS affective (p < 0.01), and GAF (p < 0.001). However, there was no significant change in subscale of BPRS manic, DAI-10, DIEPSS, or SSTS but significant positive correlations were found between SSTS and DAI-10 and GAF at baseline; a negative correlation was found between SSTS and BPRS. The findings of the study suggested the benefit of using the COMPASS in conjunction with RLAI to decrease patients’ psychiatric symptomatology and improve treatment satisfaction. In addition, patient satisfaction was found to be an important factor to be considered by the psychiatrist.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Zhao, Y. , Yasuhara, Y. , Tanioka, T. , Sakamaki, S. , Tomotake, M. , King, B. , Locsin, R. and Iwata, N. (2015) The Effect of a Psycho-Educational Program on Psychiatric Symptoms, Drug Attitude and Treatment Satisfaction of Patients with Schizophrenia. Open Journal of Psychiatry, 5, 229-237. doi: 10.4236/ojpsych.2015.53027.

References

[1] Burns, T. (2009) Knowledge about Antipsychotic Long-Acting Injections: Bridging That Gap. British Journal of Psychiatry. Supplement, 52, S5-S6. http://dx.doi.org/10.1192/bjp.195.52.s5
[2] Patel, M.X., de Zoysa, N., Bernadt, M. and David, A.S. (2008) A Cross-Sectional Study of Patients’ Perspectives on Adherence to Antipsychotic Medication: Depot versus Oral. Journal of Clinical Psychiatry, 69, 1548-1556. http://dx.doi.org/10.4088/JCP.v69n1004
[3] Kane, J.M. (2011) Improving Treatment Adherence in Patients with Schizophrenia. Journal of Clinical Psychiatry, 72, e28. http://dx.doi.org/10.4088/jcp.9101tx2c
[4] Burton, S.C. (2005) Strategies for Improving Adherence to Second-Generation Antipsychotics in Patients with Schizophrenia by Increasing Ease of Use. Journal of Psychiatric Practice, 11, 369-378. http://dx.doi.org/10.1097/00131746-200511000-00003
[5] Lincoln, T.M., Wilhelm, K. and Nestoriuc, Y. (2007) Effectiveness of Psychoeducation for Relapse, Symptoms, Knowledge, Adherence and Functioning in Psychotic Disorders: A Meta-Analysis. Schizophrenia Research, 96, 232-245. http://dx.doi.org/10.1016/j.schres.2007.07.022
[6] Yamaguchi, H., Takahashi, A., Takano, A. and Kojima, T. (2006) Direct Effects of Short-Term Psychoeducational Intervention for Relatives of Patients with Schizophrenia in Japan. Psychiatry and Clinical Neurosciences, 60, 590-597. http://dx.doi.org/10.1111/j.1440-1819.2006.01563.x
[7] Guo, X., Zhai, J., Liu, Z., Fang, M., Wang, B., Wang, C., Hu, B., Sun, X., Lv, L., Lu, Z., Ma, C., He, X., Guo, T., Xie, S., Wu, R., Xue, Z., Chen, J., Twamley, E.W., Jin, H. and Zhao, J. (2010) Effect of Antipsychotic Medication Alone vs Combined with Psychosocial Intervention on Outcomes of Early-Stage Schizophrenia: A Randomized, 1-Year Study. Archives of General Psychiatry, 67, 895-904. http://dx.doi.org/10.1001/archgenpsychiatry.2010.105
[8] Sweileh, W.M., Ihbesheh, M.S., Jarar, I.S., Sawalha, A.F., Abu Taha, A.S., Zyoud, S.H. and Morisky, D.E. (2012) Antipsychotic Medication Adherence and Satisfaction among Palestinian People with Schizophrenia. Current Clinical Pharmacology, 7, 49-55.
http://dx.doi.org/10.2174/157488412799218761
[9] Leucht, C., Heres, S., Kane, J.M., Kissling, W., Davis, J.M. and Leucht, S. (2011) Oral versus Depot Antipsychotic Drugs for Schizophrenia—A Critical Systematic Review and Meta-Analysis of Randomised Long-Term Trials. Schizophrenia Research, 127, 83-92.
http://dx.doi.org/10.1016/j.schres.2010.11.020
[10] Lee, S.H., Choi, T.K., Suh, S., Kim, Y.W., Kim, B., Lee, E. and Yook, K.H. (2010) Effectiveness of a Psychosocial Intervention for Relapse Prevention in Patients with Schizophrenia Receiving Risperidone via Long-Acting Injection. Psychiatry Research, 175, 195-199.
http://dx.doi.org/10.1016/j.psychres.2008.06.043
[11] Zhao, Y., Kishi, T., Iwata, N. and Ikeda, M. (2013) Combination Treatment with Risperidone Long-Acting Injection and Psychoeducational Approaches for Preventing Relapse in Schizophrenia. Neuropsychiatric Disease and Treatment, 9, 1655-1659. http://dx.doi.org/10.2147/NDT.S52317
[12] Inada, T. (1996) Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms. In: Yagi, G., Ed., Commentary on the DIEPSS and Guide to Its Usage, Seiwa Publishers, Toyko, 3-54. (In Japanese)
[13] Galuppi, A., Turola, M.C., Nanni, M.G., Mazzoni, P. and Grassi, L. (2010) Schizophrenia and Quality of Life: How Important Are Symptoms and Functioning? International Journal of Mental Health Systems, 4, 31. http://dx.doi.org/10.1186/1752-4458-4-31
[14] Kurtz, M.M., Bronfeld, M. and Rose, J. (2012) Cognitive and Social Cognitive Predictors of Change in Objective versus Subjective Quality-of-Life in Rehabilitation for Schizophrenia. Psychiatry Research, 200, 102-107. http://dx.doi.org/10.1016/j.psychres.2012.06.025
[15] Kim, J.H. and Kim, M.J. (2009) Association of Adverse Drug Effects with Subjective Well-Being in Patients with Schizophrenia Receiving Stable Doses of Risperidone. Clinical Neuropharmacology, 32, 250-253. http://dx.doi.org/10.1097/WNF.0b013e3181a5d08c
[16] Helldin, L., Kane, J., Karilampi, U., Norlander, T. and Archer, T. (2008) Experience of Quality of Life and Attitude to Care and Treatment in Patients with Schizophrenia: Role of Cross-Sectional Remission. International Journal of Psychiatry in Clinical Practice, 12, 97-104.
http://dx.doi.org/10.1080/13651500701660007
[17] Xia, J., Merinder, L.B. and Belgamwar, M.R. (2011) Psychoeducation for Schizophrenia. Cochrane Database of Systematic Reviews, 6, Article ID: CD002831.
http://dx.doi.org/10.1002/14651858.CD002831.pub2
[18] Aki, H., Tomotake, M., Kaneda, Y., Iga, J., Kinouchi, S., Shibuya-Tayoshi, S., Tayoshi, S.Y., Motoki, I., Moriguchi, K., Sumitani, S., Yamauchi, K., Taniguchi, T., Ishimoto, Y., Ueno, S. and Ohmori, T. (2008) Subjective and Objective Quality of Life, Levels of Life Skills, and Their Clinical Determinants in Outpatients with Schizophrenia. Psychiatry Research, 158, 19-25.
http://dx.doi.org/10.1016/j.psychres.2006.05.017
[19] Medina, E., Salvà, J., Ampudia, R., Maurino, J. and Larumbe, J. ( 2012) Short-Term Clinical Stability and Lack of Insight Are Associated with a Negative Attitude Towards Antipsychotic Treatment at Discharge in Patients with Schizophrenia and Bipolar Disorder. Patient Prefer Adherence, 6, 623-629. http://dx.doi.org/10.2147/PPA.S34345

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.